Natera, Inc. and CytoDyn Inc. have announced a strategic collaboration to enhance the understanding of circulating tumor DNA (ctDNA) dynamics in metastatic colorectal cancer (mCRC). Natera will assess clinical trial samples from CytoDyn's CLOVER Phase 2 study, utilizing its personalized Signatera assay to evaluate molecular residual disease (MRD) and treatment responses associated with leronlimab, a monoclonal antibody targeting the CCR5 receptor. This partnership will leverage Natera's extensive oncology database, which contains over 2 million plasma timepoints, to conduct customized real-world data analyses. These analyses aim to provide insights into patient populations, treatment patterns, and ctDNA response rates, which may help inform future clinical development strategies for leronlimab. CytoDyn's CEO, Jacob Lalezari, emphasized the importance of this collaboration in gaining valuable insights into ctDNA response kinetics and disease progression, which could guide future oncology treatment strategies. The collaboration is expected to complement ongoing translational and biomarker analyses from the CLOVER study, further characterizing treatment responses and informing development strategies for leronlimab.